HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Impact of first-line antifungal agents on the outcomes and costs of candidemia.

Abstract
Candida species are the leading causes of invasive fungal infection among hospitalized patients and are responsible for major economic burdens. The goals of this study were to estimate the costs directly associated with the treatment of candidemia and factors associated with increased costs, as well as the impact of first-line antifungal agents on the outcomes and costs. A retrospective study was conducted in a sample of 199 patients from four university-affiliated tertiary care hospitals in Korea over 1 year. Only costs attributable to the treatment of candidemia were estimated by reviewing resource utilization during treatment. Risk factors for increased costs, treatment outcome, and hospital length of stay (LOS) were analyzed. Approximately 65% of the patients were treated with fluconazole, and 28% were treated with conventional amphotericin B. The overall treatment success rate was 52.8%, and the 30-day mortality rate was 47.9%. Hematologic malignancy, need for mechanical ventilation, and treatment failure of first-line antifungal agents were independent risk factors for mortality. The mean total cost for the treatment of candidemia was $4,743 per patient. Intensive care unit stay at candidemia onset and antifungal switch to second-line agents were independent risk factors for increased costs. The LOS was also significantly longer in patients who switched antifungal agents to second-line drugs. Antifungal switch to second-line agents for any reasons was the only modifiable risk factor of increased costs and LOS. Choosing an appropriate first-line antifungal agent is crucial for better outcomes and reduced hospital costs of candidemia.
AuthorsYoung Eun Ha, Kyong Ran Peck, Eun-Jeong Joo, Shin Woo Kim, Sook-In Jung, Hyun Ha Chang, Kyong Hwa Park, Sang Hoon Han
JournalAntimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 56 Issue 7 Pg. 3950-6 (Jul 2012) ISSN: 1098-6596 [Electronic] United States
PMID22526315 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antifungal Agents
  • Drug Combinations
  • liposomal amphotericin B
  • Deoxycholic Acid
  • Itraconazole
  • Amphotericin B
  • amphotericin B, deoxycholate drug combination
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Amphotericin B (adverse effects, economics, therapeutic use)
  • Antifungal Agents (adverse effects, economics, therapeutic use)
  • Candidemia (drug therapy, economics, microbiology)
  • Deoxycholic Acid (adverse effects, economics, therapeutic use)
  • Drug Combinations
  • Female
  • Humans
  • Itraconazole (adverse effects, economics, therapeutic use)
  • Male
  • Middle Aged
  • Retrospective Studies

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: